Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Biodel reports phase IIa data for BIOD-531 in patients with type 2 diabetes

Aug. 13, 2014

India CSIR discloses new agents for diabetes and dyslipidemia

Aug. 12, 2014

FDA approves Invokamet for type 2 diabetes

Aug. 11, 2014

Aegis Therapeutics seeks partnering for exenatide nasal spray

Aug. 6, 2014

Yuhan reports novel glucokinase activators

Aug. 6, 2014

Genzyme receives label expansion for Lumizyme in the U.S.

Aug. 5, 2014

Development of a novel, potent enzyme inhibitor for the treatment of type 2 diabetes

Aug. 5, 2014

FDA approves empagliflozin for type 2 diabetes

Aug. 4, 2014

Regeneron and Sanofi to use priority review voucher for alirocumab BLA

Aug. 4, 2014

Esteve confirms initiation of natural history study for Sanfilippo A syndrome

Aug. 4, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 8, 2026.
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld Science
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis
BioWorld Science
Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the...